Abstract
Despite high expectations of economic returns, large investments in regenerative medicine technology have yet to materialize, partly due to a lack of proven business and investment models, regulatory hurdles, and a greater focus on cost-effectiveness for reimbursement decisions by payors. Adoption of new economic modeling methods will better link investment decisions to value-based criteria of health systems.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 89-93 |
| Number of pages | 5 |
| Journal | Stem Cells and Development |
| Volume | 22 |
| Issue number | SUPPL.1 |
| DOIs | |
| Publication status | Published - 1 Dec 2013 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Value-engineered translation for regenerative medicine: Meeting the needs of health systems'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver